Cargando…

Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists’ recommendations for active treatment or active surveillance: a randomized clinical utility trial

BACKGROUND: Of the more than 1.1 million men diagnosed worldwide annually with prostate cancer, the majority have indolent tumors. Distinguishing between aggressive and indolent cancer is an important clinical challenge. The current approaches for assessing tumor aggressiveness are recognized as ins...

Descripción completa

Detalles Bibliográficos
Autores principales: Peabody, John W., DeMaria, Lisa M., Tamondong-Lachica, Diana, Florentino, Jhiedon, Czarina Acelajado, M., Ouenes, Othman, Richie, Jerome P., Burgon, Trever
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496184/
https://www.ncbi.nlm.nih.gov/pubmed/28673277
http://dx.doi.org/10.1186/s12894-017-0243-1
_version_ 1783247921538400256
author Peabody, John W.
DeMaria, Lisa M.
Tamondong-Lachica, Diana
Florentino, Jhiedon
Czarina Acelajado, M.
Ouenes, Othman
Richie, Jerome P.
Burgon, Trever
author_facet Peabody, John W.
DeMaria, Lisa M.
Tamondong-Lachica, Diana
Florentino, Jhiedon
Czarina Acelajado, M.
Ouenes, Othman
Richie, Jerome P.
Burgon, Trever
author_sort Peabody, John W.
collection PubMed
description BACKGROUND: Of the more than 1.1 million men diagnosed worldwide annually with prostate cancer, the majority have indolent tumors. Distinguishing between aggressive and indolent cancer is an important clinical challenge. The current approaches for assessing tumor aggressiveness are recognized as insufficient. A validated protein-based assay has been shown to predict tumor aggressiveness from prostate biopsy. The main objective of this study was to measure the clinical utility of this new assay in the management of early-stage prostate cancer. METHODS: One hundred twenty nine board-certified urologists were asked to participate in a randomized, two-arm experiment. We collected data over 2 rounds using simulated clinical cases administered via an online platform. The cases were all newly diagnosed Gleason 3 + 3 or 3 + 4 prostate camcer patients. Urologists in the intervention arm received a 15-min webinar on this protein-based assay and given assay test results for their simulated patients in round 2. Each case had a preferred recommendation of either active surveillance or active treatment. The measured outcome was rate of preferred recommendation, defined as urologists who recommended the proper treatment course. Analyses were done using difference-in-difference estimations. RESULTS: Using multinomial logistical regression, urologists who were given the assay results were significantly more likely to choose the preferred recommendation (active surveillance or active treatment) compared to controls (p = 0.004). These urologists were also significantly more likely to involve their patients in the treatment decision compared to controls (p = 0.001). CONCLUSIONS: By providing additional information to inform the physician’s treatment plan, a protein-based assay shows demonstrable clinical utility confirmed through a rigorous randomized controlled study design and regression analyses to test for effects.
format Online
Article
Text
id pubmed-5496184
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54961842017-07-05 Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists’ recommendations for active treatment or active surveillance: a randomized clinical utility trial Peabody, John W. DeMaria, Lisa M. Tamondong-Lachica, Diana Florentino, Jhiedon Czarina Acelajado, M. Ouenes, Othman Richie, Jerome P. Burgon, Trever BMC Urol Research Article BACKGROUND: Of the more than 1.1 million men diagnosed worldwide annually with prostate cancer, the majority have indolent tumors. Distinguishing between aggressive and indolent cancer is an important clinical challenge. The current approaches for assessing tumor aggressiveness are recognized as insufficient. A validated protein-based assay has been shown to predict tumor aggressiveness from prostate biopsy. The main objective of this study was to measure the clinical utility of this new assay in the management of early-stage prostate cancer. METHODS: One hundred twenty nine board-certified urologists were asked to participate in a randomized, two-arm experiment. We collected data over 2 rounds using simulated clinical cases administered via an online platform. The cases were all newly diagnosed Gleason 3 + 3 or 3 + 4 prostate camcer patients. Urologists in the intervention arm received a 15-min webinar on this protein-based assay and given assay test results for their simulated patients in round 2. Each case had a preferred recommendation of either active surveillance or active treatment. The measured outcome was rate of preferred recommendation, defined as urologists who recommended the proper treatment course. Analyses were done using difference-in-difference estimations. RESULTS: Using multinomial logistical regression, urologists who were given the assay results were significantly more likely to choose the preferred recommendation (active surveillance or active treatment) compared to controls (p = 0.004). These urologists were also significantly more likely to involve their patients in the treatment decision compared to controls (p = 0.001). CONCLUSIONS: By providing additional information to inform the physician’s treatment plan, a protein-based assay shows demonstrable clinical utility confirmed through a rigorous randomized controlled study design and regression analyses to test for effects. BioMed Central 2017-07-03 /pmc/articles/PMC5496184/ /pubmed/28673277 http://dx.doi.org/10.1186/s12894-017-0243-1 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Peabody, John W.
DeMaria, Lisa M.
Tamondong-Lachica, Diana
Florentino, Jhiedon
Czarina Acelajado, M.
Ouenes, Othman
Richie, Jerome P.
Burgon, Trever
Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists’ recommendations for active treatment or active surveillance: a randomized clinical utility trial
title Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists’ recommendations for active treatment or active surveillance: a randomized clinical utility trial
title_full Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists’ recommendations for active treatment or active surveillance: a randomized clinical utility trial
title_fullStr Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists’ recommendations for active treatment or active surveillance: a randomized clinical utility trial
title_full_unstemmed Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists’ recommendations for active treatment or active surveillance: a randomized clinical utility trial
title_short Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists’ recommendations for active treatment or active surveillance: a randomized clinical utility trial
title_sort impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists’ recommendations for active treatment or active surveillance: a randomized clinical utility trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496184/
https://www.ncbi.nlm.nih.gov/pubmed/28673277
http://dx.doi.org/10.1186/s12894-017-0243-1
work_keys_str_mv AT peabodyjohnw impactofaproteinbasedassaythatpredictsprostatecanceraggressivenessonurologistsrecommendationsforactivetreatmentoractivesurveillancearandomizedclinicalutilitytrial
AT demarialisam impactofaproteinbasedassaythatpredictsprostatecanceraggressivenessonurologistsrecommendationsforactivetreatmentoractivesurveillancearandomizedclinicalutilitytrial
AT tamondonglachicadiana impactofaproteinbasedassaythatpredictsprostatecanceraggressivenessonurologistsrecommendationsforactivetreatmentoractivesurveillancearandomizedclinicalutilitytrial
AT florentinojhiedon impactofaproteinbasedassaythatpredictsprostatecanceraggressivenessonurologistsrecommendationsforactivetreatmentoractivesurveillancearandomizedclinicalutilitytrial
AT czarinaacelajadom impactofaproteinbasedassaythatpredictsprostatecanceraggressivenessonurologistsrecommendationsforactivetreatmentoractivesurveillancearandomizedclinicalutilitytrial
AT ouenesothman impactofaproteinbasedassaythatpredictsprostatecanceraggressivenessonurologistsrecommendationsforactivetreatmentoractivesurveillancearandomizedclinicalutilitytrial
AT richiejeromep impactofaproteinbasedassaythatpredictsprostatecanceraggressivenessonurologistsrecommendationsforactivetreatmentoractivesurveillancearandomizedclinicalutilitytrial
AT burgontrever impactofaproteinbasedassaythatpredictsprostatecanceraggressivenessonurologistsrecommendationsforactivetreatmentoractivesurveillancearandomizedclinicalutilitytrial